Search Results - "Collins, Meghan E."

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials by Yap, Timothy A., Daver, Naval, Mahendra, Mikhila, Zhang, Jixiang, Kamiya-Matsuoka, Carlos, Meric-Bernstam, Funda, Kantarjian, Hagop M., Ravandi, Farhad, Collins, Meghan E., Francesco, Maria Emilia Di, Dumbrava, Ecaterina E., Fu, Siqing, Gao, Sisi, Gay, Jason P., Gera, Sonal, Han, Jing, Hong, David S., Jabbour, Elias J., Ju, Zhenlin, Karp, Daniel D., Lodi, Alessia, Molina, Jennifer R., Baran, Natalia, Naing, Aung, Ohanian, Maro, Pant, Shubham, Pemmaraju, Naveen, Bose, Prithviraj, Piha-Paul, Sarina A., Rodon, Jordi, Salguero, Carolina, Sasaki, Koji, Singh, Anand K., Subbiah, Vivek, Tsimberidou, Apostolia M., Xu, Quanyun A., Yilmaz, Musa, Zhang, Qi, Li, Yuan, Bristow, Christopher A., Bhattacharjee, Meenakshi B., Tiziani, Stefano, Heffernan, Timothy P., Vellano, Christopher P., Jones, Philip, Heijnen, Cobi J., Kavelaars, Annemieke, Marszalek, Joseph R., Konopleva, Marina

“…Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy, clinical benefit with OXPHOS inhibitors has yet to be achieved. Here…”
Get full text

Isolation of Synergistic Natural Products Targeting Metabolic Dysfunction in Pediatric Pre‐B Cell Acute Lymphoblastic Leukemia Using High‐Throughput Screening and Metabolomics by Collins, Meghan E, Sweeney, Shannon R., Tiziani, Stefano

“…High‐throughput screening was used to isolate synergistic compounds from a library of 136 natural products that exhibited negligible effects on non‐malignant…”
Get full text